Combination treatment targeting BAG-1 with small molecule protein-protein interaction inhibitors and HER2 with trastuzumab synergistically reduces breast cancer cell growth, which is accompanied by attenuation of protein synthesis and induction of G1/S cell cycle arrest through the ERK and AKT pathways. The gene discussed is AKT1; the disease is breast cancer.